Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
August 07 2017 - 8:00AM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing a broad pipeline of novel
product candidates based on its Targeting Protein Therapeutics
(TPTs) platform, today announced that it will host a live
conference call and webcast at 8:00 a.m. ET on Monday, August 14,
2017 to report its second quarter 2017 financial results and
provide a corporate update.
To access the conference call, please dial (844) 831-3025
(domestic) or (315) 625-6887 (international) at least five minutes
prior to the start time and refer to conference ID 63779857. An
audio webcast of the call will also be available on the Investors
& Media section of the company's website, www.elevenbio.com. An
archived webcast will be available on the Company's website
approximately two hours after the event and will be available for
30 days.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology
company advancing a broad pipeline of novel product candidates
based upon the Company's TPTs platform. The Company's TPTs
incorporate a tumor-targeting antibody fragment and a protein
cytotoxic payload into a single protein molecule in order to
achieve focused tumor cell killing. The Company believes its TPT
approach offers significant advantages in treating cancer over
existing antibody drug conjugate technologies. The Company believes
its TPTs provide effective tumor targeting with broader cancer
cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistance mechanisms. Additionally, the Company believes that its
TPT's cancer cell-killing properties promote an anti-tumor immune
response that will potentially combine well with immune oncology
drugs such as checkpoint inhibitors. For more information please
refer to the Company's website at www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170807005304/en/
Stern Investor RelationsHannah
Deresiewiczhannahd@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024